Philip Morris International ($PM) said the U.S. Food and Drug Administration has authorized 20 variants of its Zyn nicotine pouches to be marketed as posing a lower health risk than cigarettes. The authorization allows Philip Morris to state that switching completely from cigarettes to Zyn lowers the risk of diseases including lung cancer, heart disease, stroke, emphysema, and chronic bronchitis, marking the first modified-risk authorization for a nicotine pouch product.
- The FDA authorized modified-risk marketing claims for 20 Zyn nicotine pouch products.
- Philip Morris can market that using Zyn instead of cigarettes lowers the risk of several smoking-related diseases.
- Zyn is the first nicotine pouch to receive this type of FDA authorization.
- The decision comes as nicotine pouches remain the fastest-growing nicotine category in the U.S., where Zyn has recently faced increased competition.
- Federal lobbying disclosures show Altria Group's lobbying activity, including millions of dollars reported in 2026 across tobacco, nicotine, tax, FDA, and regulatory issues.
Relevant Companies
- Philip Morris International ($PM) – The FDA authorization allows the company to market Zyn with modified-risk claims, potentially strengthening its position in the U.S. nicotine pouch market.
- Altria Group ($MO) – As the owner of Philip Morris USA and a major U.S. tobacco company, Altria could benefit if regulatory recognition of reduced-risk nicotine products accelerates broader category adoption.
- British American Tobacco ($BTI) – Competing reduced-risk nicotine products may face increased competitive pressure following the FDA's authorization for Zyn.
Editor’s Note: This is a developing story. This article may be updated as more details become available.
